A Narrative Review of Potential Future Antidiabetic Drugs: Should We Expect More?

被引：17
作者：
Chikara G. [1 ]
Sharma P.K. [2 ]
Dwivedi P. [2 ]
Charan J. [2 ]
Ambwani S. [2 ]
Singh S. [2 ]
机构：
[1] Dr. Sampurnanand Medical College-Jodhpur, Residency Road, Sector-D, Shastri Nagar, Jodhpur, 342003, Rajasthan
[2] All India Institute of Medical Sciences (AIIMS)-Jodhpur, Basni Industrial Area Phase-2, Jodhpur, 342005, Rajasthan
来源：
Indian Journal of Clinical Biochemistry | 2018年 / 33卷 / 2期
关键词：
ASBT inhibitors; Diabetes mellitus type 2; Glimins; mTOT agonists; Precision medicine;
D O I：
10.1007/s12291-017-0668-z
中图分类号：
学科分类号：
摘要：
Prevalence of diabetes mellitus, a chronic metabolic disease characterized by hyperglycemia, is growing worldwide. The majority of the cases belong to type 2 diabetes mellitus (T2DM). Globally, India ranks second in terms of diabetes prevalence among adults. Currently available classes of therapeutic agents are used alone or in combinations but seldom achieve treatment targets. Diverse pathophysiology and the need of therapeutic agents with more favourable pharmacokinetic-pharmacodynamics profile make newer drug discoveries in the field of T2DM essential. A large number of molecules, some with novel mechanisms, are in pipeline. The essence of this review is to track and discuss these potential agents, based on their developmental stages, especially those in phase 3 or phase 2. Unique molecules are being developed for existing drug classes like insulins, DPP-4 inhibitors, GLP-1 analogues; and under newer classes like dual/pan PPAR agonists, dual SGLT1/SGLT2 inhibitors, glimins, anti-inflammatory agents, glucokinase activators, G-protein coupled receptor agonists, hybrid peptide agonists, apical sodium-dependent bile acid transporter (ASBT) inhibitors, glucagon receptor antagonists etc. The heterogeneous clinical presentation and therapeutic outcomes in phenotypically similar patients is a clue to think beyond the standard treatment strategy. © 2017, Association of Clinical Biochemists of India.
引用
收藏
页码：121 / 131
页数：10
相关论文
共 88 条
[1]  
International Diabetes Federation, (2015)
[2]  
DeFronzo R.A., Pathogenesis of type 2 diabetes: metabolic and molecular implications for identifying diabetes genes, Diabetes Res, 5, pp. 177-269, (1997)
[3]  
Grant R.W., Devita N.G., Singer D.E., Meigs J.B., Polypharmacy and medication adherence in patients with type 2 diabetes, Diabetes Care, 26, 5, pp. 1408-1412, (2003)
[4]  
Jayant D., Lawrence B., Richard G., Factor influencing patient acceptability of diabetes treatment regimens, Clin Diabetes, 18, 2, pp. 61-67, (2000)
[5]  
Ho P.M., Rumsfeld J.S., Masoudi F.A., McClure D.L., Plomondon M.E., Steiner J.F., Et al., Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus, Arch Intern Med, 166, pp. 1836-1841, (2006)
[6]  
Currie C.J., Peyrot M., Morgan C.L., Poole C.D., Jenkins-Jones S., Rubin R.R., Et al., The impact of treatment noncompliance on mortality in people with type 2 diabetes, Diabetes Care, 35, pp. 1279-1284, (2012)
[7]  
Hay M., Thomas D.W., Craighead J.L., Economides C., Rosenthal J., Clinical development success rates for investigational drugs, Nat Biotechnol, 32, pp. 40-51, (2014)
[8]  
Bolen S., Feldman L., Vassy J., Wilson L., Yeh H.C., Marinopoulos S., Et al., Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus, Ann Intern Med, 147, pp. 386-399, (2007)
[9]  
Egan A.G., Blind E., Dunder K., Graeff P.A., Hummer B.T., Bourcier T., Et al., Pancreatic safety of incretin based drugs—FDA and EMA assessment, N Engl J Med, 370, pp. 794-797, (2014)
[10]  
Steiner S., Hompesch M., Pohl R., Simms P., Flacke F., Mohr T., Et al., A novel insulin formulation with a more rapid onset of action, Diabetologia, 51, pp. 1602-1606, (2008)
123456789